Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CARG, VES13, G8 Scales in Predicting Drug Toxicity in Patients Receiving Nivolumab

NCT05564923 is registered in ClinicalTrials.gov with Namik Kemal University as lead sponsor.

NCT NCT05564923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05564923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CARG, VES13, G8 Scales in Predicting Drug Toxicity in Patients Receiving Nivolumab
Lead sponsor
Namik Kemal University
Phase
Observational
Overall status
Unknown status
Start date
September 2, 2022
Completion date
August 17, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nivolumab related toxicity